{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:04:32Z","timestamp":1787313872854,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1136\/ijgc-2022-004178","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T11:38:16Z","timestamp":1692877096000},"page":"1715-1723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent\/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct02715284","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Scott","family":"Goulden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-7861","authenticated-orcid":false,"given":"Kiera","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulya","family":"Sen Nikitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmi","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Knott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Schade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-004178_bb0010","first-page":"209","article-title":"Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2022-004178_bb0015","unstructured":"National Cancer Institute . Cancer STAT facts: uterine cancer 2022. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/corp.html [Accessed 25 Mar 2022]."},{"key":"10.1136\/ijgc-2022-004178_bb0020","author":"World Health Organization","year":"2020","journal-title":"Globocan 2020. Corpus uteri. 2020"},{"key":"10.1136\/ijgc-2022-004178_bb0025","unstructured":"Cancer Research UK . Uterine cancer statistics 2022. Available: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/uterine-cancer [Accessed 25 Mar 2022]."},{"key":"10.1136\/ijgc-2022-004178_bb0030","first-page":"179","article-title":"Factors predicting recurrent endometrial cancer","volume":"5","author":"Huijgens","year":"2013","journal-title":"Facts Views Vis Obgyn"},{"key":"10.1136\/ijgc-2022-004178_bb0035","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ygyno.2006.02.011","article-title":"Follow-up after primary therapy for endometrial cancer: a systematic review","volume":"101","author":"Fung-Kee-Fung","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2022-004178_bb0045","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejogrb.2017.04.015","article-title":"BGCS uterine cancer guidelines: recommendations for practice","volume":"213","author":"Sundar","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2022-004178_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3802\/jgo.2011.22.1.3","article-title":"Multivariate survival analysis of the patients with recurrent endometrial cancer","volume":"22","author":"Odagiri","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2022.06.011","article-title":"Previously treated recurrent or advanced endometrial cancer in England: a real-world observational analysis","volume":"166","author":"Heffernan","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0060","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0065","unstructured":"National Institute for Health and Care Excellence . Dostarlimab for previously treated advanced or recurrent endometrial cancer with high Microsatellite instability or mismatch repair deficiency 2022. Available: https:\/\/www.nice.org.uk\/guidance\/ta779\/chapter\/3-Committee-discussion [Accessed 13 May 2022]."},{"key":"10.1136\/ijgc-2022-004178_bb0070","unstructured":"National Institute for Health and Care Excellence . Testing strategies for Lynch syndrome in people with endometrial cancer 2020. Available: https:\/\/www.nice.org.uk\/guidance\/dg42\/resources\/testing-strategies-for-lynch-syndrome-in-people-with-endometrial-cancer-pdf-1053807829189 [Accessed 13 May 2022]."},{"key":"10.1136\/ijgc-2022-004178_bb0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1136\/ijgc-2022-004178_bb0080","unstructured":"GSK . Jemperli summary of product characteristics 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jemperli-epar-product-information_en.pdf [Accessed 30 Mar 2022]."},{"key":"10.1136\/ijgc-2022-004178_bb0085","unstructured":"GSK . Jemperli prescribing information 2021. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761223s000lbl.pdf [Accessed 30 Mar 2022]."},{"key":"10.1136\/ijgc-2022-004178_bb0090","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 Monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0095","unstructured":"World Health Organization . Cancer over time 2022. Available: https:\/\/gco.iarc.fr\/overtime\/en [Accessed 25 Mar 2022]."},{"key":"10.1136\/ijgc-2022-004178_bb0100","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2147\/CLEP.S242097","article-title":"Synthetic and external controls in clinical trials - a primer for researchers","volume":"12","author":"Thorlund","year":"2020","journal-title":"Clin Epidemiol"},{"key":"10.1136\/ijgc-2022-004178_bb0105","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ije\/dyz076","article-title":"Data resource profile: National cancer registration dataset in England","volume":"49","author":"Henson","year":"2020","journal-title":"Int J Epidemiol"},{"key":"10.1136\/ijgc-2022-004178_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"Oaknin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1136\/ijgc-2022-004178_bb0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0090-8258(02)00068-9","article-title":"Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study","volume":"88","author":"Lincoln","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0120","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1200\/JCO.2022.40.16_suppl.5509","article-title":"Dostarlimab in advanced\/recurrent mismatch repair deficient\/microsatellite instability-high or proficient\/stable endometrial cancer: the GARNET study","volume":"40","author":"Oaknin","year":"2022","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-004178_bb0125","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O\u2019Malley","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0130","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-004178_bb0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdw542","article-title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","volume":"28","author":"Stelloo","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113319","article-title":"Gynecological cancers caused by deficient mismatch repair and microsatellite instability","volume":"12","author":"Deshpande","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2022-004178_bb0145","doi-asserted-by":"crossref","first-page":"5652","DOI":"10.18632\/oncotarget.23790","article-title":"Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer","volume":"9","author":"Yamashita","year":"2018","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2022-004178_bb0150","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.1016\/S1470-2045(13)70591-6","article-title":"Classification of endometrial carcinoma: more than two types","volume":"15","author":"Murali","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004178_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-020-01124-6","article-title":"Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1136\/ijgc-2022-004178_bb0160","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1172\/JCI129197","article-title":"Opportunities and challenges in using real-world data for health care","volume":"130","author":"Rudrapatna","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1136\/ijgc-2022-004178_bb0165","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1634\/theoncologist.2019-0175","article-title":"Median survival or mean survival: which measure is the most appropriate for patients, physicians, and policymakers","volume":"24","author":"Ben-Aharon","year":"2019","journal-title":"Oncologist"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24017687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-004178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:28:41Z","timestamp":1753234121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24017687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S1048891X24017687"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-004178","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of dostarlimab versus chemotherapy in post-platinum patients with recurrent\/advanced endometrial cancer: data from the GARNET trial and the National Cancer Registration Service in England","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-004178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}